(Q44924769)

7 December 2017

title

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine (English)

1 reference

7 December 2017

main subject

anti-retroviral agent

0 references

1 reference

Elinore F McCance-Katz

1

1 reference

7 December 2017

David E Moody

2

1 reference

7 December 2017

Gene D Morse

3

1 reference

7 December 2017

Gerald Friedland

4

1 reference

7 December 2017

Patricia Pade

5

1 reference

7 December 2017

Jennifer Baker

6

1 reference

7 December 2017

Anika Alvanzo

7

1 reference

7 December 2017

Patrick Smith

8

1 reference

7 December 2017

Abayomi Ogundele

9

1 reference

7 December 2017

Peter Jatlow

10

1 reference

7 December 2017

Petrie M Rainey

11

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Clinical Infectious Diseases

7 December 2017

published in

1 reference

7 December 2017

volume

43 Suppl 4

1 reference

7 December 2017

page(s)

S224-34

1 reference

Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents

7 December 2017

cites work

1 reference

Office-based buprenorphine treatment for opioid-dependent patients

21 January 2018

1 reference

Clinical pharmacology of buprenorphine: ceiling effects at high doses

21 January 2018

1 reference

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

21 January 2018

1 reference

Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine

21 January 2018

1 reference

Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir

21 January 2018

1 reference

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

21 January 2018

1 reference

Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.

21 January 2018

1 reference

21 January 2018

1 reference

Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma

21 January 2018

1 reference

Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects

21 January 2018

1 reference

Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation

21 January 2018

1 reference

Two New Rating Scales for Opiate Withdrawal

21 January 2018

1 reference

Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/508187

1 reference

7 December 2017

1 reference